secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001558370-23-017412
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio's MB-106 CAR-T interim data selected for ASH; complete responses in FL
--------------------------------------------------------------------------------

- Interim Phase 1/2 data for MB-106 (CD20-targeted CAR-T) accepted as poster at ASH Dec 9-12, 2023.
- At dose level 1 (3.3x10^6 cells/kg): two FL patients achieved complete response, WM patient VGPR, HCL-v stable disease with transfusion independence.
- Safety: 3 patients Grade 1 CRS, no ICANS or dose-limiting toxicities; outpatient infusion allowed.
- Patients heavily pre-treated (median 5.5 prior lines); WM patient had nine prior treatments including auto-SCT.
- Pivotal Phase 2 WM trial expected to start mid-2024 with top-line data possible by mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023017412/0001558370-23-017412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023017412/tmb-20231102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer